Nike’s price-to-earnings ratio is now well below its long-term average, but is still above that of the S P 500.
Nike’s price-to-earnings ratio is now well below its long-term average, but is still above that of the S&P 500.
Same desk, different stories
In this week’s edition of InnovationRx, we look the billionaire dentist, Wegovy by subscription, Kailera’s planned IPO, and more.
SpaceX reportedly filed confidential IPO paperwork, setting the stage for a listing as soon as June.
The Last of Us season 3's release date is hugely far away given that filming has only justs begun now, a year after season 2 aired.
The largest US-listed exchange-traded funds tracking single Asian countries from India to Taiwan suffered record outflows in March, just ahead of a massive rebound in the region’s equities on the first day of April.
One live music bar firm in Glasgow says it is facing a near six-fold increase and may have to lay off staff.
The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit the market.